NCT01272375View on ClinicalTrials.gov

This Study Is To Estimate The Time Course Of Pf-04764793 In The Blood Following Dosing By Oral Inhalation From Dry Powder Inhalers

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

January 31, 2011

Primary Completion Date

May 31, 2011

Study Completion Date

May 31, 2011

Conditions
Healthy
Interventions
DRUG

Treatment A

PF-04764793 250/50 using inhaler A

DRUG

Treatment B

PF-04764793 250/50 using inhaler A

DRUG

Treatment C

PF-04764793 250/50 using inhaler A

DRUG

Treatment D

PF-04764793 250/50 using inhaler A

DRUG

Treatment E

PF-04764793 250/50 using inhaler B

DRUG

Treatment F

PF-04764793 250/50 using inhaler B

DRUG

Treatment G

PF-04764793 250/50 using inhaler B

Trial Locations (1)

188770

Pfizer Investigational Site, Singapore

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT01272375 - This Study Is To Estimate The Time Course Of Pf-04764793 In The Blood Following Dosing By Oral Inhalation From Dry Powder Inhalers | Biotech Hunter | Biotech Hunter